229 related articles for article (PubMed ID: 22785249)
21. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
Mohty M; Boiron JM; Damaj G; Michallet AS; Bay JO; Faucher C; Perreau V; Bilger K; Coso D; Stoppa AM; Tabrizi R; Gastaut JA; Michallet M; Maraninchi D; Blaise D
Bone Marrow Transplant; 2004 Jul; 34(1):77-84. PubMed ID: 15133485
[TBL] [Abstract][Full Text] [Related]
22. Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation.
Brissot E; Cahu X; Guillaume T; Delaunay J; Ayari S; Peterlin P; Le Bourgeois A; Harousseau JL; Milpied N; Bene MC; Moreau P; Mohty M; Chevallier P
Ann Hematol; 2015 Apr; 94(4):663-9. PubMed ID: 25409914
[TBL] [Abstract][Full Text] [Related]
23. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
24. CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin.
Dong L; Wu T; Zhang MJ; Gao ZY; Lu DP
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1515-24. PubMed ID: 18022582
[TBL] [Abstract][Full Text] [Related]
25. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
26. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes.
Kebriaei P; Kline J; Stock W; Kasza K; Le Beau MM; Larson RA; van Besien K
Bone Marrow Transplant; 2005 May; 35(10):965-70. PubMed ID: 15806131
[TBL] [Abstract][Full Text] [Related]
27. CD8+ T cell dose affects development of acute graft-vs-host disease following reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Mohty M; Bagattini S; Chabannon C; Faucher C; Bardou VJ; Bilger K; Vey N; Gaugler B; Stoppa AM; Coso D; Ladaique P; Olive D; Viens P; Blaise D
Exp Hematol; 2004 Nov; 32(11):1097-102. PubMed ID: 15539088
[TBL] [Abstract][Full Text] [Related]
28. High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia.
Shigematsu A; Kobayashi N; Yasui H; Shindo M; Kakinoki Y; Koda K; Iyama S; Kuroda H; Tsutsumi Y; Imamura M; Teshima T
Biol Blood Marrow Transplant; 2014 Jun; 20(6):801-5. PubMed ID: 24565990
[TBL] [Abstract][Full Text] [Related]
29. Enteral versus Parenteral Nutrition as Nutritional Support after Allogeneic Hematopoietic Stem Cell Transplantation: a Systematic Review and Meta-Analysis.
Zama D; Gori D; Muratore E; Leardini D; Rallo F; Turroni S; Prete A; Brigidi P; Pession A; Masetti R
Transplant Cell Ther; 2021 Feb; 27(2):180.e1-180.e8. PubMed ID: 33830034
[TBL] [Abstract][Full Text] [Related]
30. Radiation-free regimens result in similar outcomes of allogeneic hematopoietic progenitor cell transplantation in patients aged >or=50 years compared to younger adults with low-risk disease.
Farag SS; Elder PJ; Marcucci G; Penza S; Mrozek E; Molina A; Lin T; Avalos BR; Copelan E
Bone Marrow Transplant; 2003 Jan; 31(2):87-93. PubMed ID: 12621488
[TBL] [Abstract][Full Text] [Related]
31. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
32. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
[TBL] [Abstract][Full Text] [Related]
33. Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Imataki O; Nakatani S; Hasegawa T; Kondo M; Ichihashi K; Araki M; Ishida T; Kim SW; Mori S; Fukuda T; Tobinai K; Tanosaki R; Makimoto A; Takaue Y
Am J Hematol; 2006 Oct; 81(10):747-52. PubMed ID: 16865687
[TBL] [Abstract][Full Text] [Related]
34. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia.
Lim Z; Brand R; Martino R; van Biezen A; Finke J; Bacigalupo A; Beelen D; Devergie A; Alessandrino E; Willemze R; Ruutu T; Boogaerts M; Falda M; Jouet JP; Niederwieser D; Kroger N; Mufti GJ; De Witte TM
J Clin Oncol; 2010 Jan; 28(3):405-11. PubMed ID: 20008642
[TBL] [Abstract][Full Text] [Related]
36. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F; Szydlo RM; Brissot E; Chevallier P; Guillaume T; Delaunay J; Ayari S; Dubruille V; Le Gouill S; Mahe B; Gastinne T; Blin N; Saulquin B; Harousseau JL; Moreau P; Mohty M
Biol Blood Marrow Transplant; 2010 Jan; 16(1):28-34. PubMed ID: 20053329
[TBL] [Abstract][Full Text] [Related]
37. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
Lim ZY; Fiaccadori V; Gandhi S; Hayden J; Kenyon M; Ireland R; Marsh J; Ho AY; Mufti GJ; Pagliuca A
Leuk Res; 2010 Jun; 34(6):723-7. PubMed ID: 19944463
[TBL] [Abstract][Full Text] [Related]
38. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
40. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
Guièze R; Damaj G; Pereira B; Robin M; Chevallier P; Michallet M; Vigouroux S; Beguin Y; Blaise D; El Cheikh J; Roos-Weil D; Thiebaut A; Rohrlich PS; Huynh A; Cornillon J; Contentin N; Suarez F; Lioure B; Mohty M; Maillard N; Clement L; François S; Guillerm G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2016 Feb; 22(2):240-247. PubMed ID: 26256942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
